Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Intangibles (2016 - 2025)

Amphastar Pharmaceuticals has reported Intangibles over the past 13 years, most recently at $29.2 million for Q4 2025.

  • Quarterly results put Intangibles at $29.2 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $29.2 million (changed 0.0% YoY), and the annual figure for FY2025 was $29.2 million, changed 0.0%.
  • Intangibles for Q4 2025 was $29.2 million at Amphastar Pharmaceuticals, roughly flat from $29.2 million in the prior quarter.
  • Over the last five years, Intangibles for AMPH hit a ceiling of $29.2 million in Q3 2021 and a floor of $29.2 million in Q1 2021.
  • Median Intangibles over the past 5 years was $29.2 million (2021), compared with a mean of $29.2 million.
  • Peak annual rise in Intangibles hit 0.09% in 2021, while the deepest fall reached 0.09% in 2021.
  • Amphastar Pharmaceuticals' Intangibles stood at $29.2 million in 2021, then changed by 0.0% to $29.2 million in 2022, then changed by 0.0% to $29.2 million in 2023, then changed by 0.0% to $29.2 million in 2024, then changed by 0.0% to $29.2 million in 2025.
  • The last three reported values for Intangibles were $29.2 million (Q4 2025), $29.2 million (Q3 2025), and $29.2 million (Q2 2025) per Business Quant data.